Gounder, Mrinal M.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 4,071

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 3,380

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4 -Amplified Well-Differentiated or Dedifferentiated Liposarcoma

Dickson, M. A., Tap, W. D., Keohan, M. L., D'Angelo, S. P., Gounder, M. M., Antonescu, C. R., Landa, J., Qin, L.-X., Rathbone, D. D., Condy, M. M., et al. (2013) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentAdvanced Breast Cancer Therapies

Cited by 399

Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

Nacev, B. A., Sanchez-Vega, F., Smith, S. A., Antonescu, C. R., Rosenbaum, E., Shi, H., Tang, C., Socci, N. D., Rana, S., Gularte-Mérida, R., et al. (2022) · Nature Communications

Sarcoma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 232

Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy

Francis, J. H., Habib, L. A., Abramson, D. H., Yannuzzi, L. A., Heinemann, M., Gounder, M. M., Grisham, R. N., Postow, M. A., Shoushtari, A. N., Chi, P., et al. (2017) · Ophthalmology

Drug-Induced Ocular ToxicityRetinal Diseases and Treatments

Cited by 141

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

Gluck, W. L., Gounder, M. M., Frank, R., Eskens, F., Blay, J. Y., Cassier, P. A., Soria, J.-C., Chawla, S., de Weger, V., Wagner, A. J., et al. (2020) · Investigational New Drugs

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 127

The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study

LoRusso, P., Yamamoto, N., Patel, M. R., Laurie, S. A., Bauer, T. M., Geng, J., Davenport, T., Teufel, M., Li, J., Lahmar, M., et al. (2023) · Cancer Discovery

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 101

Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

D’Angelo, S. P., Richards, A. L., Conley, A. P., Woo, H. J., Dickson, M. A., Gounder, M., Kelly, C., Keohan, M. L., Movva, S., Thornton, K., et al. (2022) · Nature Communications

Cancer Immunotherapy and BiomarkersSarcoma Diagnosis and Treatment

Cited by 60

Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas

Gounder, M. M., Bauer, T. M., Schwartz, G. K., LoRusso, P., Kumar, P., Kato, K., Tao, B., Hong, Y., Patel, P., & Hong, D. (2020) · European Journal of Cancer

Sarcoma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 19